ALX Oncology Holdings Inc. (ALXO) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti

ALX Oncology Holdings (ALXO) korporativ emblemasi va logotipi

ALX Oncology Holdings (ALXO) o'zining eritrotsitlarni tejaydigan mahsulotining noyobligi tufayli ulkan narx belgilash imkoniyatiga ega. Ushbu ishlanmaning xavfsizlik profili kompaniyaga narxlar urushiga kirmasdan turib, bozorning sezilarli ulushini egallash imkonini beradi. -1.70 ko'rsatkichi aks etgan aksiya narxi tarixi, o'sish faqat patent murakkabliklari va qat'iy xavfsizlik talablari bilan cheklangan manzaranı to'ldiradi. Biznes o'simtalarga qarshi kurashish uchun immunologik asoslangan dori vositalarini yaratishga tayanadi.

ALXO ALX Oncology Holdings Inc.: Narx-foyda koeffitsiyenti 04.07.2022 - 18.11.2026 oraligʻida

ALX Oncology Holdings kompaniyasining tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning har tomonlama tahlili:ALXO ALX Oncology
ALX Oncology ishlab chiqargan mahsulot

ALX Oncology Holdings (ALXO) o'zining CD47-blokatori pipeline-larini agressiv ravishda rivojlantirishga e'tibor qaratgan holda, kompaniyani yuqori texnologiyali biofarmatsevtika sektorining klassik vakili sifatida namoyish etmoqda. Kompaniyaning tarixiy P/E grafigini tahlil qilish orqali investor aktiv qiymatining joriy samaradorligiga nisbatan qanchalik shishirilganligini aniqlash uchun bozor kapitalizatsiyasining sof foydaga nisbatini baholaydi. Ushbu koeffitsiyentning dinamikasi evorpacept-ning inqilobiy chiqishlariga bo'lgan kutishlar va biznesning haqiqiy fundamental barqarorligi o'rtasidagi korrelyatsiyani aniqlash imkonini beradi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning foydaga nisbati ImmunityBio IBRX|P/E multiplikatori IMCR|Janux Therapeutics (JANX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Arcus Biosciences Inc - Narx-foyda koeffitsiyenti|Zymeworks (ZYME) - Kapitalizatsiyaning foydaga nisbati|TNGX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati IOVA (Iovance Biotherapeutics, Inc.)|IMTX: P/E multiplikatori|XNCR - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati compasstherapeutics.com|Narx-foyda koeffitsiyenti replimune.com (REPL)|Narxning foydaga nisbati Lyell (LYEL)|Narx-foyda koeffitsiyenti Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori Compugen Ltd. CGEN|IOBT - Narxning foydaga nisbati|STRO (sutrobio.com) - Narx-foyda multiplikatori|MiNK Therapeutics, Inc (INKT) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Werewolf Therapeutics (HOWL)|Narx-foyda koeffitsiyenti IMMX|CUE (Cue Biopharma, Inc.) - Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti PDSB (PDS Biotechnology)|Bozor narxining sof foydaga nisbati SONN|P/E multiplikatori MAIA (MAIA Biotechnology, Inc.)|Kompaniya qiymatining sof foydaga nisbati LIMN|Lava Tx - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NextCure Corporation|Leap Tx (LPTX) - Narxning foydaga nisbati|Intensity Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|SNSE (Sensei Bio) - P/E multiplikatori|P/E multiplikatori Theriva Biologics Inc|Narxning foydaga nisbati gritstonebio.com (GRTS)|P/E multiplikatori Kineta Bio (KA)|NexImmune Inc - Narx-foyda koeffitsiyenti|turnstonebio.com (TSBX) - Kapitalizatsiyaning foydaga nisbati|VCNX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HARP (Harpoon Therapeutics, Inc.)